184 related articles for article (PubMed ID: 37493896)
1. A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy.
Lo Piccolo L; Umegawachi T; Yeewa R; Potikanond S; Nimlamool W; Prachayasittikul V; Gotoh Y; Yoshida H; Yamaguchi M; Jantrapirom S
Neurotherapeutics; 2023 Sep; 20(5):1330-1346. PubMed ID: 37493896
[TBL] [Abstract][Full Text] [Related]
2. Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis.
Liu Y; Yan D; Yang L; Chen X; Hu C; Chen M
Transl Neurodegener; 2024 Apr; 13(1):20. PubMed ID: 38600555
[No Abstract] [Full Text] [Related]
3. New clinical insight in amyotrophic lateral sclerosis and innovative clinical development from the non-profit repurposing trial of the old drug guanabenz.
Ambrosini A; Dalla Bella E; Ravasi M; Melazzini M; Lauria G
Front Med (Lausanne); 2024; 11():1407912. PubMed ID: 38915767
[TBL] [Abstract][Full Text] [Related]
4. Specific vulnerability of iPSC-derived motor neurons with TDP-43 gene mutation to oxidative stress.
Onda-Ohto A; Hasegawa-Ogawa M; Matsuno H; Shiraishi T; Bono K; Hiraki H; Kanegae Y; Iguchi Y; Okano HJ
Mol Brain; 2023 Jul; 16(1):62. PubMed ID: 37496071
[TBL] [Abstract][Full Text] [Related]
5. Aberrant dynein function promotes TDP-43 aggregation and upregulation of p62 in male mice harboring transgenic human TDP-43.
Christoforidou E; Simoes FA; Gordon D; Talbot K; Hafezparast M
Amyotroph Lateral Scler Frontotemporal Degener; 2023 Jul; ():1-10. PubMed ID: 37498094
[TBL] [Abstract][Full Text] [Related]
6. Monomerization of TDP-43 is a key determinant for inducing TDP-43 pathology in amyotrophic lateral sclerosis.
Oiwa K; Watanabe S; Onodera K; Iguchi Y; Kinoshita Y; Komine O; Sobue A; Okada Y; Katsuno M; Yamanaka K
Sci Adv; 2023 Aug; 9(31):eadf6895. PubMed ID: 37540751
[TBL] [Abstract][Full Text] [Related]
7. TDP-43 differentially propagates to induce antero- and retrograde degeneration in the corticospinal circuits in mouse focal ALS models.
Tsuboguchi S; Nakamura Y; Ishihara T; Kato T; Sato T; Koyama A; Mori H; Koike Y; Onodera O; Ueno M
Acta Neuropathol; 2023 Oct; 146(4):611-629. PubMed ID: 37555859
[TBL] [Abstract][Full Text] [Related]
8. Low T-cell reactivity to TDP-43 peptides in ALS.
Ramachandran S; Grozdanov V; Leins B; Kandler K; Witzel S; Mulaw M; Ludolph AC; Weishaupt JH; Danzer KM
Front Immunol; 2023; 14():1193507. PubMed ID: 37545536
[TBL] [Abstract][Full Text] [Related]
9. Nutritional and metabolic factors in amyotrophic lateral sclerosis.
Ludolph A; Dupuis L; Kasarskis E; Steyn F; Ngo S; McDermott C
Nat Rev Neurol; 2023 Sep; 19(9):511-524. PubMed ID: 37500993
[TBL] [Abstract][Full Text] [Related]
10. Caspase 3 exhibits a yeast metacaspase proteostasis function that protects mitochondria from toxic TDP43 aggregates.
Brunette S; Sharma A; Bell R; Puente L; Megeney LA
Microb Cell; 2023 Aug; 10(8):157-169. PubMed ID: 37545643
[TBL] [Abstract][Full Text] [Related]
11. The MLO-down on TDP-43.
Dykstra M; Barmada SJ
Brain; 2023 Sep; 146(9):3565-3567. PubMed ID: 37540028
[TBL] [Abstract][Full Text] [Related]
12. Human herpesvirus 8 ORF57 protein is able to reduce TDP-43 pathology: network analysis identifies interacting pathways.
Webber CJ; Murphy CN; Rondón-Ortiz AN; van der Spek SJF; Kelly EX; Lampl NM; Chiesa G; Khalil AS; Emili A; Wolozin B
Hum Mol Genet; 2023 Oct; 32(20):2966-2980. PubMed ID: 37522762
[TBL] [Abstract][Full Text] [Related]
13. TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP.
Arseni D; Chen R; Murzin AG; Peak-Chew SY; Garringer HJ; Newell KL; Kametani F; Robinson AC; Vidal R; Ghetti B; Hasegawa M; Ryskeldi-Falcon B
Nature; 2023 Aug; 620(7975):898-903. PubMed ID: 37532939
[TBL] [Abstract][Full Text] [Related]
14. UBQLN2 and HSP70 participate in Parkin-mediated mitophagy by facilitating outer mitochondrial membrane rupture.
Ma Q; Xin J; Peng Q; Li N; Sun S; Hou H; Ma G; Wang N; Zhang L; Tam KY; Dussmann H; Prehn JH; Wang H; Ying Z
EMBO Rep; 2023 Sep; 24(9):e55859. PubMed ID: 37501540
[TBL] [Abstract][Full Text] [Related]
15. Astrocytic response mediated by the CLU risk allele inhibits OPC proliferation and myelination in a human iPSC model.
Liu Z; Chao J; Wang C; Sun G; Roeth D; Liu W; Chen X; Li L; Tian E; Feng L; Davtyan H; Blurton-Jones M; Kalkum M; Shi Y
Cell Rep; 2023 Aug; 42(8):112841. PubMed ID: 37494190
[TBL] [Abstract][Full Text] [Related]
16. Flanking regions, amyloid cores, and polymorphism: the potential interplay underlying structural diversity.
Bhopatkar AA; Kayed R
J Biol Chem; 2023 Sep; 299(9):105122. PubMed ID: 37536631
[TBL] [Abstract][Full Text] [Related]
17. A panel of TDP-43-regulated splicing events verifies loss of TDP-43 function in amyotrophic lateral sclerosis brain tissue.
Cao MC; Ryan B; Wu J; Curtis MA; Faull RLM; Dragunow M; Scotter EL
Neurobiol Dis; 2023 Sep; 185():106245. PubMed ID: 37527763
[TBL] [Abstract][Full Text] [Related]
18.
Broce IJ; Sirkis DW; Nillo RM; Bonham LW; Lee SE; Miller B; Castruita P; Sturm VE; Sugrue LS; Desikan RS; Yokoyama JS
bioRxiv; 2023 Aug; ():. PubMed ID: 37503230
[TBL] [Abstract][Full Text] [Related]
19. Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.
Haben S; Ciplea AI; Tokic M; Timmesfeld N; Thiel S; Gold R; Langer-Gould AM; Hellwig K
J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):151-157. PubMed ID: 37536925
[TBL] [Abstract][Full Text] [Related]
20. Repeated mild traumatic brain injury triggers pathology in asymptomatic C9ORF72 transgenic mice.
Kahriman A; Bouley J; Tuncali I; Dogan EO; Pereira M; Luu T; Bosco DA; Jaber S; Peters OM; Brown RH; Henninger N
Brain; 2023 Dec; 146(12):5139-5152. PubMed ID: 37527465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
